The Project 5h6m2e

The CUIDA Chagas Project – “Communities United for Innovation, Development and Care for Chagas Disease” – is led by the National Institute of Infectious Diseases (INI) of the Oswaldo Cruz Foundation (Fiocruz), Brazil. It has logistical, istrative and financial from the Foundation for Scientific and Technological Development of Health (Fiotec) and works in partnership with the National Institute of Health Laboratories (INLASA), from Bolivia; the National Health Institute (INS), from Colombia; the National Malaria Eradication Service (SENEPA), from Paraguay; and FIND, the global alliance for diagnostics. It is funded by Unitaid and co-funded by the Brazilian Ministry of Health. 5n552l

The project combines implementation research, diagnostic and clinical innovation, community engagement and market interventions. Its objective is to contribute to the elimination of vertical transmission of Chagas disease in Latin America, improving and expanding access to diagnosis, treatment and care for affected people.

CUIDA Chagas represents an unprecedented advance in achieving the elimination of vertical transmission of Chagas disease in our region. It reinforces the importance of cooperation and regional integration to overcome the many challenges faced by Latin American peoples in the face of neglected diseases.

The CUIDA Chagas Project – “Communities United for Innovation, Development and Care for Chagas Disease” – is led by the National Institute of Infectious Diseases (INI) of the Oswaldo Cruz Foundation (Fiocruz), Brazil. It has logistical, istrative and financial from the Foundation for Scientific and Technological Development of Health (Fiotec) and works in partnership with the National Institute of Health Laboratories (INLASA), from Bolivia; the National Health Institute (INS), from Colombia; the National Malaria Eradication Service (SENEPA), from Paraguay; and FIND, the global alliance for diagnostics. It is funded by Unitaid and co-funded by the Brazilian Ministry of Health.

The project combines implementation research, diagnostic and clinical innovation, community engagement and market interventions. Its objective is to contribute to the elimination of vertical transmission of Chagas disease in Latin America, improving and expanding access to diagnosis, treatment and care for affected people.

CUIDA Chagas represents an unprecedented advance in achieving the elimination of vertical transmission of Chagas disease in our region. It reinforces the importance of cooperation and regional integration to overcome the many challenges faced by Latin American peoples in the face of neglected diseases.

CUIDA Chagas current numbers 5n6v32

4 2r5c4k

Countries c4k6r

41 33526x

Municipalities 2h2756

+220 5l4n3v

Health centers 5j326

+253.000 65e3u

Expected number of people to be evaluated until 2026 k3w4n

8.400 4i58

Expected number of people to be treated until 2026 1m603t

Chagas disease 346b3d

Chagas disease is a neglected tropical disease that mainly affects impoverished and vulnerable populations in 21 Latin American countries. However, as a result of migration, its scope is global, with a presence on nearly all continents.

Chagas disease is caused by the protozoan Trypanosoma cruzi (T. cruzi) that resides in blood and tissue of the human body. The best-known mode of transmission is through with feces/urine of triatomine bugs (kissing bugs), already infected with the parasite. However, there are also other forms of transmission: through blood transfusions, organ transplants, consumption of contaminated drinks or food and transmission during pregnancy and/or childbirth.

It is important to emphasize that there is no transmission of Chagas disease through saliva or sexual . In addition, there is no need for Chagas disease positive mothers to discontinue breastfeeding, unless they are in the acute phase the disease, suffer from immunosuppression which could lead to reactivation of the disease, or experience bleeding nipples.

Without treatment, between 30% and 40% of those affected develop serious cardiac or gastrointestinal complications. Each year, approximately 12,000 people die as a result of complications related to Chagas disease.

However, if diagnosed and treated in time, the serious stages of the disease can be avoided and, in certain cases, affected people may be cured.

Responsible, equitable, integrated and innovative actions contribute to improving the quality of life and the life expectancy of people affected by Chagas disease.

Chagas disease is a neglected tropical disease that mainly affects impoverished and vulnerable populations in 21 Latin American countries. However, as a result of migration, its scope is global, with a presence on nearly all continents.

Chagas disease is caused by the protozoan Trypanosoma cruzi (T. cruzi) that resides in blood and tissue of the human body. The best-known mode of transmission is through with feces/urine of triatomine bugs (kissing bugs), already infected with the parasite. However, there are also other forms of transmission: through blood transfusions, organ transplants, consumption of contaminated drinks or food and transmission during pregnancy and/or childbirth.

It is important to emphasize that there is no transmission of Chagas disease through saliva or sexual . In addition, there is no need for Chagas disease positive mothers to discontinue breastfeeding, unless they are in the acute phase the disease, suffer from immunosuppression which could lead to reactivation of the disease, or experience bleeding nipples.

Without treatment, between 30% and 40% of those affected develop serious cardiac or gastrointestinal complications. Each year, approximately 12,000 people die as a result of complications related to Chagas disease.

However, if diagnosed and treated in time, the serious stages of the disease can be avoided and, in certain cases, affected people may be cured.

Responsible, equitable, integrated and innovative actions contribute to improving the quality of life and the life expectancy of people affected by Chagas disease.

THE WORLD HEALTH ORGANIZATION (WHO) ESTIMATES THAT BETWEEN 6 TO 8 MILLION PEOPLE LIVING IN RURAL AND URBAN AREAS ARE AFFECTED BY CHAGAS DISEASE. MORE THAN ONE MILLION WOMEN OF CHILDBEARING AGE GIVE BIRTH TO 8 TO 15 THOUSAND BABIES AFFECTED BY THE DISEASE.

VERTICAL TRANSMISSION OF CHAGAS DISEASE OCCURS DURING PREGNANCY AND/OR DELIVERY. IT IS ALSO KNOWN AS “CONGENITAL” OR “MOTHER TO CHILD” TRANSMISSION AND IS RESPONSIBLE FOR UP TO A THIRD OF ANNUAL NEW CASES OF THE DISEASE.

The Consortium CUIDA Chagas 395y

The CUIDA Chagas consortium was created in order to change the scenario of neglect that surrounds Chagas disease. The consortium is made up of governmental and non-governmental institutions that are widely recognized in the area of public health.

Based on strategic alliances and a consolidated governance structure, each consortium member contributes with specific actions in the different territories where the project is implemented and provides technical and scientific input.

This form of organization and management provides the project with institutional legitimacy, technical-scientific solidity, and sustainability. By working closely together with government institutions, the results and evidence generated by CUIDA Chagas may be incorporated in public policies, thereby guaranteeing the right to adequate health care for people and communities affected by Chagas disease in Latin America.

The CUIDA Chagas consortium was created in order to change the scenario of neglect that surrounds Chagas disease. The consortium is made up of governmental and non-governmental institutions that are widely recognized in the area of public health.

Based on strategic alliances and a consolidated governance structure, each consortium member contributes with specific actions in the different territories where the project is implemented and provides technical and scientific input.

This form of organization and management provides the project with institutional legitimacy, technical-scientific solidity, and sustainability. By working closely together with government institutions, the results and evidence generated by CUIDA Chagas may be incorporated in public policies, thereby guaranteeing the right to adequate health care for people and communities affected by Chagas disease in Latin America.

Core Team 2z4311

Fundação Oswaldo Cruz (Fiocruz)
Avenida Brasil 4036, sala 102 – Manguinhos – Rio de Janeiro, RJ, Brasil.
CEP: 21.040-361
[email protected]

Andrea Silvestre 4b1i6m

Grant Principal Investigator 5f1d3i

Debbie Vermeij 3k144x

Project Director 1hn26

Eduardo Sholl 573b3f

Project Manager 24xh

Camila Garroux 16k3

1v3f1p

Henny
Heredia

Data Manager kfw

Javier Abi-Saab 4b4r2

Larissa de Paula 2c416v

Project Assistant 5r53b

Israel Molina 2b6k1n

Clinical Trials Principal Investigator 5a1h5c

Monique Gurgel 67724y

Clinical Trials Senior Monitor r6r2s

Franciana Rosa 1h3h3b

Validation Study Principal Investigator 1f18

Luiz Vilarinho 6b6j62

Market Access Coordinator 274s6g

Pedro Henrique Campanini 2023t

Human Subject Research Officer 4s5d4c

Yerly Useche 55v

Cost-effectiveness Study Assistant 4y4j6w

Tiago Nery 5d56q

Political Advisor n3f4z

Eloan Pinheiro 3y1n3g

Technical Specialist Treatment 2m5d50

Fiotec Team

Luiz Abiel Martins 1p1f3o

Project Analyst Senior 6b6c6w

Raquel Silva 1u1w4s

Project Analyst Junior 496vq

Eduardo Mello 5o3n5c

Financial Analyst 6e15z